Zosano Pharma, a biotech developing a transdermal delivery system to treat osteoporosis, announced terms for its IPO on Wednesday. The Fremont, CA-based company plans to raise $70 million by offering 6.4 million shares at a price range of $10 to $12. At the midpoint of the proposed range, it would command a fully diluted market value of $139 million.
Zosano Pharma, which was spun out of Johnson & Johnson (JNJ) in 2006 and booked $3 million in license fee revenue for the 12 months ended March 31, 2014, plans to list on the NASDAQ under the symbol ZSAN. Wedbush PacGrow, Ladenburg Thalmann and Roth Capital are the joint bookrunners on the deal. No pricing date was disclosed.
